Branded ‘EPA3G,’ the supplement is available in sachet form and contains almost three grams of the omega 3 oil eicosapentaenoic acid (EPA) that can be once daily as a drinkable emulsion.
According to the firm, the format overcomes current issues with omega-3 consumption such as the dosage needed to deliver meaningful health benefits and a lack of alternatives to bulky, difficult-to-swallow capsules.
“With this agreement, people will now have a differentiated, value-added omega-3 product, which is effective and easy to use,” says Luciano Conde, CEO of Noventure.
“We are very pleased to work with Azur, together we will keep building strong partnerships based on a shared understanding of user’s needs and pursue market opportunities whilst growing together.”
EPA and DHA market
The agreement sees Noventure acquire the rights to license EPA3G to companies with the “marketing expertise and knowledge in the commercialisation of high-end food supplements”.
Noventure are permitted to exercise these licensing rights to all EU members and associated states, the UK, the Balkans, Russia, Ukraine, Eurasian countries, Mexico, Taiwan and several African states. Financial terms of the agreement have not been disclosed.
With reference to the global EPA and DHA market expected growth of 8.26% during 2020 – 2025, Julio Boza, CEO of Azur attributes the reasons for this growth as down to the “increased prevalence of lifestyle diseases and people choosing preventive healthcare measures.
“Consumer desire for high effectiveness and bioavailability has also ensured manufacturers seek more highly concentrated forms to better provide efficacious doses of EPA. We are delighted to work with Noventure.
We believe this technology will allow people to satisfy their omega-3 requirements in a convenient drinkable format. This is a great example of transforming bright science and technology into breakthrough, sustainable commercial solutions and is an example of how to work and grow together.”